Business Wire

Guidewire Announces 2017.2 Release of InsurancePlatform

Jaa

CONNECTIONS 2017 – Guidewire Software, Inc. (NYSE: GWRE), a provider of software products to general insurers, today announced the 2017.2 release of Guidewire InsurancePlatform™. This release includes enhancements to Guidewire’s Core, Data, and Digital product families. These enhancements enable insurer operations to be smarter, faster, and more connected in order to better engage with customers, agents/brokers, and employees. This greater level of engagement, in turn, allows Guidewire customers to provide these users with compelling experiences and users journeys.

“We see Engagement Era demands compelling insurers to re-imagine their consumer and agent/broker interactions, and more fully empower their employees,” said Ayan Sarkar, vice president, Digital, Guidewire Software. “The enhancements available in InsurancePlatform 2017.2 will further support their efforts.”

“We are pleased to offer InsurancePlatform 2017.2 to the market,” said Ali Kheirolomoom, chief product officer, Guidewire Software. “Our tradition of providing high-quality software continues with this release. Designed to help insurers better compete in today’s era of engagement, the enhancements to many of the products in InsurancePlatform 2017.2 provide the foundation they need to succeed.”

Through new versions of DataHub, InfoCenter, Predictive Analytics, Predictive Analytics Solution Packs, InsurancePlatform enables insurers to work smarter and make faster data-driven decisions through predictive, guided processes, API-driven design and integrations, and more pre-built content. At the same time, new versions of Guidewire Digital™ products offer collaboration enhancements that allow InsurancePlatform customers to create a more connected experience for improved policyholder self-service capabilities.

Key release highlights include:

  • Guidewire DataHub™ 9.2 continues to simplify content extension needs and reduce implementation costs with ETL (Extract, Transform, Load) automation and configuration enhancements. Support for claims activities and improvements in the earnings storage and processing provide users with a holistic picture of the operational efficiency in claims processing along with an increased confidence in earnings statements.
  • Guidewire InfoCenter™ 9.2 helps improve user productivity and engagement with the upgrade to IBM Cognos 11. Advanced self-service capabilities will make InfoCenter users smarter with fast answers to their business questions with little to no IT involvement.
  • Guidewire Predictive Analytics™ 6.2 expands machine learning capabilities to mine unstructured data to identify additional indicators of claim severity. Guidewire Predictive Analytics is now available globally on Amazon Web Services (AWS) to help alleviate customer concerns about compliance with local and regional data security and privacy regulations.
  • New Guidewire Predictive Analytics Solution Packs for Subrogation and Litigation Risk Detection integrated to Guidewire ClaimCenter® to enable a smart claims operation. These integrated use cases identify and escalate claims with opportunity for third-party cost recovery and claims that have a higher risk of entering litigation. Improvements to the model deployment and core systems integration process helps Solution Packs users achieve quicker return on their investments.
  • Guidewire Digital 7.0 provides mobile-first quoting experiences that enable consumers and policyholders to quote and buy insurance from anywhere. They can scan their vehicle identification numbers to look up the vehicle they want to insure, scan their driver’s licenses to pre-fill the information needed for fast quoting, and receive visual confirmation of the type of vehicle they are insuring.

About Guidewire InsurancePlatform

Guidewire InsurancePlatform™ combines three elements – core operations, data and analytics, and digital engagement – that work together to enhance an insurer’s ability to respond to industry changes and better engage and empower their customers, agents/brokers, and employees.

About Guidewire Software

Guidewire delivers the software general insurers need to adapt and succeed in a time of rapid industry change. We combine three elements – core operations, data and analytics, and digital engagement – into an insurance platform that enhances insurers’ ability to engage and empower their customers and employees. More than 300 general insurers around the world have selected Guidewire. For more information, please visit www.guidewire.com. Follow us on twitter: @Guidewire_PandC.

NOTE: Guidewire, Guidewire Software, Guidewire ClaimCenter, Guidewire PolicyCenter, and Guidewire BillingCenter are registered trademarks of Guidewire Software, Inc. in the United States and/or other countries.

Contact information

Guidewire Software
Diana Stott, +1 650-356-4941
Director, Communications
dstott@guidewire.com
or
onechocolate Communications
Daniel Couzens, +44 (0)20 7437 0227
guidewire@onechocolatecomms.co.uk
or
Guidewire Software (UK) Ltd
Louise Bradley, +44 (0)7474 837 860
lbradley@guidewire.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

New data presented at the American Academy of Dermatology show LEO Pharma’s Kyntheum® (brodalumab) improves psoriasis on the nail19.2.2018 09:00Tiedote

NOT FOR DISTRIBUTION IN THE UNITED STATES OR UNITED KINGDOM: LEO Pharma today announced new data demonstrating long-term improvements in psoriasis on the nail with Kyntheum® (brodalumab) when compared to placebo or ustekinumab.1 Psoriasis on the nail, which is challenging to treat,2 affects approximately half of the estimated 125 million people living with psoriasis worldwide.2,3 The data were presented at the 76th annual American Academy of Dermatology (AAD) meeting in San Diego, California, US. Psoriasis is a common, chronic, immune-mediated, inflammatory disease that primarily involves the skin, but also impacts emotional, psychological and physical health.4 The heavy and far-reaching burden of the disease can be disabling and stigmatising with a substantial negative impact on those affected and their families.4 Due to the visible nature of the condition, psoriasis on the nail can be particularly upsetting for patients.4 In moderate to severe cases, psoriasis on the nail can be pain

OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers18.2.2018 00:00Tiedote

Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im

CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 11:00Tiedote

Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates

Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 21:26Tiedote

Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a

General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 20:05Tiedote

General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges

Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 12:03Tiedote

Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme